Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma

Siwen Hu-Lieskovan; Stephen Mok; Blanca Homet Moreno; Jennifer Tsoi; Lidia Robert; Lucas Goedert; Elaine M. Pinheiro; Richard C. Koya; Thomas G. Graeber; Begoña Comin-Anduix; Antoni Ribas

doi:10.1126/scitranslmed.aaa4691

Research ArticleCancer

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF^V600E melanoma

Siwen Hu-Lieskovan¹,
Stephen Mok¹,
Blanca Homet Moreno¹,²,
Jennifer Tsoi³,⁴,
Lidia Robert¹,
Lucas Goedert¹,
Elaine M. Pinheiro⁵,
Richard C. Koya¹,*,
Thomas G. Graeber³,⁴,⁶,
Begoña Comin-Anduix⁶,⁷ and
Antoni Ribas¹,⁴,⁶,⁷,†

¹Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
²Division of Translational Oncology, Carlos III Health Institute, Madrid 28029, Spain.
³Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.
⁴Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.
⁵Merck Research Laboratories, Boston, MA 02115, USA.
⁶Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
⁷Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.

↵†Corresponding author. E-mail: aribas{at}mednet.ucla.edu

↵* Present address: Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

See allHide authors and affiliations

Science Translational Medicine 18 Mar 2015:
Vol. 7, Issue 279, pp. 279ra41
DOI: 10.1126/scitranslmed.aaa4691

Siwen Hu-Lieskovan

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stephen Mok

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Blanca Homet Moreno

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

2Division of Translational Oncology, Carlos III Health Institute, Madrid 28029, Spain.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jennifer Tsoi

3Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.

4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lidia Robert

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lucas Goedert

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elaine M. Pinheiro

5Merck Research Laboratories, Boston, MA 02115, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Richard C. Koya

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas G. Graeber

3Crump Institute for Molecular Imaging, UCLA, Los Angeles, CA 90095, USA.

4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.

6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Begoña Comin-Anduix

6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.

7Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Antoni Ribas

1Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.

4Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA 90095, USA.

6Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.

7Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA 90095, USA.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: aribas@mednet.ucla.edu

Article
Figures & Data
Info & Metrics
eLetters
PDF

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Submit a Response to This Article

Compose eLetter

Title

Contents

More information about text formats

Plain text

Plain text
No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First name and middle name First or given name, e.g. 'Peter'. Last Name Your last, or family, name, e.g. 'MacMoody'. Email Your email address, e.g. higgs-boson@gmail.com Role / Occupation Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests?

Yes

Please describe the competing interests

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

No eLetters have been published for this article.

View Full Text

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF^V600E melanoma

Plain text

Vertical Tabs

Science Translational Medicine

Article Tools